Adalimumab biosimilar - Alteogen/Cristalia
Latest Information Update: 31 Dec 2021
At a glance
- Originator Alteogen
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Nootropics; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 28 Jun 2019 No recent reports of development identified for research development in Autoimmune-disorders in South Korea (SC, Injection)
- 12 May 2015 Early research in Autoimmune disorders in South Korea (SC)